These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38705597)

  • 1. A pharmacodynamic assay to monitor treatment with the hypomethylating cytosine analogs, decitabine and azacitidine.
    Jacobberger JW; Woost PG
    Methods Cell Biol; 2024; 186():131-150. PubMed ID: 38705597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
    Saunthararajah Y; Sekeres M; Advani A; Mahfouz R; Durkin L; Radivoyevitch T; Englehaupt R; Juersivich J; Cooper K; Husseinzadeh H; Przychodzen B; Rump M; Hobson S; Earl M; Sobecks R; Dean R; Reu F; Tiu R; Hamilton B; Copelan E; Lichtin A; Hsi E; Kalaycio M; Maciejewski J
    J Clin Invest; 2015 Mar; 125(3):1043-55. PubMed ID: 25621498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
    Liu Z; Liu S; Xie Z; Blum W; Perrotti D; Paschka P; Klisovic R; Byrd J; Chan KK; Marcucci G
    Nucleic Acids Res; 2007; 35(5):e31. PubMed ID: 17264127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.
    Ghoshal K; Datta J; Majumder S; Bai S; Kutay H; Motiwala T; Jacob ST
    Mol Cell Biol; 2005 Jun; 25(11):4727-41. PubMed ID: 15899874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of demethylating agents in hematology.
    Navada SC; Steinmann J; Lübbert M; Silverman LR
    J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
    Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
    Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.
    Gu X; Tohme R; Tomlinson B; Sakre N; Hasipek M; Durkin L; Schuerger C; Grabowski D; Zidan AM; Radivoyevitch T; Hong C; Carraway H; Hamilton B; Sobecks R; Patel B; Jha BK; Hsi ED; Maciejewski J; Saunthararajah Y
    Leukemia; 2021 Apr; 35(4):1023-1036. PubMed ID: 32770088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells.
    Frazzi R; Cusenza VY; Pistoni M; Canovi L; Cascione L; Bertoni F; Merli F
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine in the treatment of myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Issa JP; Ravandi F
    Expert Rev Anticancer Ther; 2010 Jan; 10(1):9-22. PubMed ID: 20014881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
    Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
    Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9.
    Lin C; Xie Y; Huang W; Lin D; Lin L
    Exp Hematol; 2022 Oct; 114():43-53.e2. PubMed ID: 35908628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.